Aim: To assess glycaemic control and factors associated with poor glycaemic control at initiation of second-line therapy in the DISCOVER programme.
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The peer review history for this article is available at https://publons.com/publon/10. 1111/dom.13866. each country, and factors associated with poor glycaemic control (HbA1c >8.0%) were evaluated using hierarchical regression models.
Results: HbA1c levels were available for 80.9% of patients (across-region range
[ARR] 57.5%-97.5%); 92.2% (ARR 59.2%-99.1%) of patients had either HbA1c or fasting plasma glucose levels available. The mean HbA1c was 8.3% (ARR 7.9%-8.7%).
In total, 26.7% of patients had an HbA1c level ≥9.0%, with the highest proportions in South-East Asia (35.6%). Factors associated with having HbA1c >8.0% at initiation of second-line therapy included low education level, low country income, and longer time since T2D diagnosis.
Conclusions:
The poor levels of glycaemic control at initiation of second-line therapy suggest that intensification of glucose-lowering treatment is delayed in many patients with T2D. In some countries, HbA1c levels are not routinely measured. These given the well-established increased risk of diabetes-related complications associated with hyperglycaemia. [1] [2] [3] The UK Prospective Diabetes Study demonstrated that an absolute reduction in glycated haemoglobin (HbA1c) level of 1.0% is associated with risk reductions of 21%, 14% and 37% for diabetes-related death, myocardial infarction and microvascular complications, respectively. 1 In a 10-year postinterventional follow-up of the study cohort, early attainment of glycaemic control was associated with long-term microvascular benefits, 4 and there is also evidence that early attainment of tight glycaemic control is predictive of long-term glycaemic control. 5 On the basis of this evidence, most clinical guidelines advocate a target HbA1c level of either <7.0% or ≤6.5% depending on additional patient-specific factors such as age, duration of diabetes, comorbidities, and risk of hypoglycaemia. [6] [7] [8] [9] [10] Treatment intensification is recommended when patients remain above their HbA1c targets for >3 months after the last intervention. Despite these recommendations, available data, mainly from Europe and North America, indicate poor attainment of glycaemic targets and infrequent implementation of timely treatment intensification. [11] [12] [13] [14] [15] [16] Moreover, real-world data on the management of T2D are scarce in many low-and middle-income countries, in which the rising disease prevalence is a concern. DISCOVER is a 3-year, global, prospective, observational study programme designed to describe the disease management patterns and a broad range of associated outcomes, including glycaemic control, in patients with T2D initiating a second-line glucose-lowering treatment (defined as adding a glucose-lowering drug or switching between therapies) after first-line (defined as the first pharmacological treatment given for the disease) oral therapy in routine clinical practice. 17, 18 The aim of the present analysis was to describe the level of glycaemic control in participants in DISCOVER at initiation of secondline glucose-lowering therapy. Factors associated with poor glycaemic control were also assessed.
| MATERIALS AND METHODS
The methods for the DISCOVER study programme have been reported in detail elsewhere 17, 18 and are summarized below.
| Study design
The global DISCOVER study programme comprises two similar, 
| Site and investigator selection
Characteristics of physicians and practices involved in the management of patients with T2D were assessed in each participating country, before the start of the study, by combining data from peerreviewed articles, information from reports published by organizations such as the WHO, and insights from key local diabetes experts who acted as national coordinating investigators. 19 The proportions of different types of physicians (primary care physicians, diabetologists, endocrinologists, cardiologists and other specialists) and practices (primary care centres, specialized diabetes centres and different types of hospitals), as well as the location of practices (urban vs rural and geographical distribution within a country), treating patients with T2D in each country were collated. A list of sites that would match these characteristics as closely as possible was then established for each country, and all sites were invited to participate in the study. 19 
| Patient recruitment
Full inclusion and exclusion criteria are shown in Table S1 . Patients aged >18 years (>20 years in Japan) with T2D, who were initiating a second-line glucose-lowering therapy were eligible for inclusion if they were not pregnant, were not undergoing dialysis, did not have a history of renal transplant, and if their first-line therapy was not an injectable agent, a herbal remedy, or a natural medicine alone. The study protocol stated that investigating physicians should invite consecutive eligible patients to participate in the study. All participating patients provided signed informed consent.
| Data collection
Data were collected at initiation of second-line glucose-lowering therapy using a standardized case report form and transferred to a central database via a web-based data capture system. Some data were extracted from existing electronic health records in Canada, Denmark, France, Norway and Sweden; in these countries, an abbreviated case report form was used. 
| Statistical analysis
For the present analysis, patients from China (n = 1293) were excluded because complete data were not available at the time of publication; therefore, the total number of patients included in the analysis was 14 699 (91.9% of the total DISCOVER population).
Descriptive data are presented as numbers and percentages for categorical variables. For continuous variables, mean (SD), median (interquartile range [IQR]), and across-region ranges (ARRs) are reported, where appropriate.
Factors associated with poor glycaemic control were assessed in patients with available HbA1c levels using hierarchical logistic regression models, with country as a random effect. HbA1c was modelled as a dichotomous variable (≤7.0% vs >7.0%, ≤8.0% vs >8.0%, and ≤9.0% Figure S1 ). 20 Complete data were available for 81.7% of patients included in the model. Separate models were also used to assess the association between receiving education on diabetes management in the past year and having poor glycaemic control. These models did not include data from Japan because data for this variable were not collected in this country. Multiple imputation was used in multivariable analyses to account for unreported data and missing values. Imputation was carried out using IVEware (University of Michigan). All other statistical analyses were carried out using the SAS statistical software system (SAS Institute, Inc., Cary, North Carolina).
| RESULTS
The demographics and characteristics of the DISCOVER cohort (N = 15 992) at initiation of second-line therapy have been reported previously. 21 Characteristics of patients with available HbA1c data (N = 11 891) are presented in Table 1 . Overall, most patients were 
| Patterns of glycaemic control by country and region
Overall, HbA1c data were available for 11 891 patients (80.9%; ARR 57.5%-98.2%), with substantial variation between countries (Tables 2   and 3 were 49.8%, 23.6% and 26.7%, respectively. These proportions varied across countries and regions ( Figure 1 ).
As expected in a population of patients initiating second-line glucose-lowering therapy, the overall proportion of patients with HbA1c <7.0% among patients with available values was low (17.4%, ARR 9.6%-25.8%; Figure 1 ). The mean (SD) HbA1c among these patients was 6.4 (0.4)% (Table 1) , and the reasons for changing therapy are presented in Table S3 . As in the overall cohort, the majority of patients (72.3%) with HbA1c <7.0% changed first-line therapy owing to lack of efficacy (ARR 56.9%-85.8%). year and the likelihood of having HbA1c levels >8.0%, when assessed in patients for whom this information was collected ( Figure S3 ). Although previous studies have reported poor levels of glycaemic control among patients with T2D, [22] [23] [24] these have mostly been conducted in populations of patients with more advanced disease than in the present study. For example, the A 1 chieve study 25 patients from 30 countries across four continents (Asia, Africa, South America and Europe); 21 of these countries were included in DIS-COVER. In A 1 chieve, the mean baseline HbA1c was higher than that in DISCOVER participants (9.5% vs 8.3%), which is likely to reflect the more severe diabetic phenotype in patients who are initiating insulin therapies. Similarly, the IMPROVE study, which included >50 000 patients across eight countries with a mean diabetes duration of 6.9 years, reported a mean HbA1c of 9.4%. 26 In the multinational, and Africa (Tunisia), many of whom were receiving insulin therapy. In the context of these studies of patients with presumably more severe diabetes than patients in the present study, the poor overall glycaemic control among DISCOVER patients is concerning.
| Factors associated with poor glycaemic control at initiation of second-line therapy

| DISCUSSION
The mean HbA1c at initiation of second-line therapy and the pro- Similarly, the authors of a study conducted in Brazil commented that kits for HbA1c measurement are not routinely provided by the National Brazilian Health Care System. 28 Aside from HbA1c monitoring, patients in lower-middle and upper-middle-income countries may also encounter problems with the availability and affordability of glucose-lowering therapies compared with patients in high-income countries. 29 Indeed, in the present study, physicians cited cost and access to treatment as reasons for choosing second-line therapy for 7.2% and 5.1% of patients, respectively, and these proportions were higher in middleincome countries than in high-income countries.
Mean levels of HbA1c were also well above guidelinerecommended values in many high-income countries. As with lower-
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No formal education Primary (1-6 years) Secondary middle and upper-middle-income countries, this finding may reflect delays in treatment intensification but for different reasons. A possible contributing factor is conservative management of patients by clinicians, as has been documented previously. 16, 30 In addition, the current stepwise approach to treatment intensification that is advocated by major treatment guidelines may lead to prolonged periods of hyperglycaemia in between steps. 15, 31 A recent analysis of patients in the United States showed no improvements in overall glycaemic control and an increase in the proportion of patients with HbA1c ≥9.0%
between 2006 and 2013, despite increased utilization of newer and costlier glucose-lowering agents among these patients. 32 These data, combined with the present data, highlight a pressing need to reevaluate existing treatment pathways for patients with T2D in order to improve glycaemic control.
Other factors associated with poor glycaemic control in multivariate analyses included younger age, male sex, low education level, and use of combination glucose-lowering therapies as first-line diabetes treatment. The inverse relationship between age and glycaemic control, while somewhat counter-intuitive, might be explained by older patients being monitored more closely by physicians than younger patients, owing to their increased comorbidity and heightened risk of complications. Authors of other studies have also hypothesized that older patients might be more motivated to look after their health and adhere to their medications than young patients. 33 Patients with a high level of education are likely to have better means to fund treatment or private medical care than less educated patients, and there is some evidence of a correlation between education level and the quality of diabetes care and outcomes. 34 This hypothesis is also consistent with the association seen in our data between lower country income and poor glycaemic control. As might be expected, having a time since diagnosis of T2D of at least 10 years compared with 0 to 5 years was also strongly correlated with poor glycaemic control. This finding is consistent with other observational studies that have demonstrated a positive relationship between disease duration and poor glycaemic control. 35, 36 The trend is likely to reflect the continual decline in β-cell function that is characteristic of T2D. These findings emphasize the importance of intensifying treatment in a timely manner once HbA1c is no longer controlled by first-line therapy.
The positive association between use of combination glucoselowering therapy as first-line treatment and poor glycaemic control is probably explained by the fact that patients with high HbA1c levels at the time of diagnosis require more intensive pharmacological treatment than patients with lower HbA1c levels, as per clinical guideline recommendations. 6 However, these intensive treatments may fail to control glycaemia adequately, which is why HbA1c levels could remain high and require initiation of second-line therapy. As described previously, 21, 37 our findings also showed a positive association between having a history of microvascular complications and having HbA1c levels >8.0%. This finding is consistent with evidence that intensive glycaemic control for a prolonged period decreases the incidence of microvascular complications. 37 However, longitudinal data from DISCOVER are required to confirm a relationship between changes in HbA1c trajectories and the incidence of diabetes complications in the present study cohort.
An interesting finding in the present study was that close to 20% of patients in the study cohort had HbA1c <7.0%. This was somewhat unexpected, given that this is a population of patients who are initiating second-line glucose-lowering therapy. The finding that the majority of these patients cited efficacy as the reason for changing treatment was also surprising, although it is notable that this proportion of patients was lower than in the overall population of patients Key strengths of the DISCOVER study programme include the large numbers of patients and inclusion of many lower-middle and upper-middle-income countries which have rarely or never been studied before. 17 The use of a standardized electronic case report form for data collection allows comparison of results within and across countries and regions. As DISCOVER is a longitudinal study, data collected during follow-up will provide valuable insights into the relationship between glycaemic control and clinical outcomes in patients with T2D across the globe. The results reported in this manuscript provide context for the interpretation of these follow-up data. There are also potential limitations of DISCOVER. Although study sites were selected with the intention of providing a patient population that was as representative of T2D care in each country as possible, 19 attainment of a truly representative sample is inherently difficult to achieve in large international studies. Reasons for this include infrastructure challenges, and the fact that some primary care centres are not set up for or willing to participate in observational research. Such practical constraints resulted in urban locations and secondary care centres being over-represented in this study. Moreover, levels of education seen in our patient population are higher on average than would be expected. This potential selection bias is likely to lead to an overestimation of the quality of diabetes care, since better-educated patients in urban locations would be expected to receive better healthcare than less educated patients in rural locations. 19 Thus, the level of glycaemic control at initiation of second-line treatment across the DISCOVER countries may be even worse than the findings reported in the present study. Despite these limitations, the efforts made to maximize representativeness resulted in the inclusion of a heterogeneous patient population, as well as a diverse range of sites and physicians. Overall, ethnicity and sex distributions of DISCOVER patients were in agreement with corresponding data from the 2017
Atlas of the International Diabetes Federation. 19 The high proportion of missing data in several countries, which might have reduced the precision of the multivariate analysis where imputation was used to compensate for unreported data, should also be acknowledged. However, this is likely to be reflective of routine clinical care; for example, HbA1c is not routinely measured in some clinical settings.
In conclusion, data from the DISCOVER study confirmed that therapeutic inertia is a global phenomenon with consistently high 
